Broadwood Partners, the largest shareholder in STAAR Surgical with a 27.5% stake, notified the company’s board yesterday (October 23, 2025) that it intends to call a special meeting of shareholders to remove several directors. The notice was issued in the context of Broadwood’s opposition to the proposed sale of STAAR to Alcon and its desire to refresh the board’s composition.
The special meeting is scheduled for October 23, 2025 and will focus on removing key board members, including Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher. Broadwood has cited concerns over the Alcon deal and the board’s handling of the transaction as reasons for the proposed removals.
Broadwood’s action reflects a significant governance challenge for STAAR Surgical, as it seeks to align the board with shareholder interests and address perceived conflicts of interest surrounding the Alcon acquisition. The company has issued a green proxy card urging shareholders to vote against the acquisition and to support the removal of the targeted directors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.